BackNLS Pharmaceutics Ltd - Warrants (25/09/2025) Overview

NLS Pharmaceutics Ltd - Warrants (25/09/2025) Current Cash

Latest current cash for NLSPW: $3.1M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$3.07M
455.83% YoYΔ $2.52M vs prior year quarter

Peer trimmed avg / median

Loading

NLS Pharmaceutics Ltd - Warrants (25/09/2025) Current Cash History

Loading

NLS Pharmaceutics Ltd - Warrants (25/09/2025) vs. peers: Current Cash Comparison

Loading

NLS Pharmaceutics Ltd - Warrants (25/09/2025) Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

NLS Pharmaceutics Ltd - Warrants (25/09/2025) (NLSPW) FAQ

As of the most recent data (June 2025), NLSPW shows a current cash of $3.1M. That compares with $550K in the prior-year period — up 455.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NLSPW's current cash is now $3.1M (was $550K) — a 455.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether NLS Pharmaceutics Ltd - Warrants (25/09/2025) is outperforming or lagging.

Tracking NLSPW's current cash over time shows whether NLS Pharmaceutics Ltd - Warrants (25/09/2025) is scaling, shrinking, or reshaping that part of the business. The current reading is $3.1M That compares with $550K in the prior-year period — up 455.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has NLS Pharmaceutics Ltd - Warrants (25/09/2025)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $3.1M) with ownership activity and broader fundamentals.

NLS Pharmaceutics Ltd - Warrants (25/09/2025)'s current cash is $3.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.